Recent data demonstrate that secondary necrosis is not an accidental epiphenomenon of apoptosis, but a finely regulated process with prominent pathophysiological and therapeutic implications. The molecular machinery that controls secondary necrosis stands out as a promising target for the development of novel drugs that may increase the immunogenicity of cancer cells succumbing to treatment.
